個別化医療におけるナノ材料：世界市場

世界の個別化医療におけるナノ材料の市場規模は、2023年の3,467億米ドルから、予測期間中は11.3%のCAGRで推移し、2028年末には5,920億米ドルの規模に成長すると予測されています。

製品タイプ別で見ると、タンパク質の部門が2023年の1,128億米ドルから、同期間中12.5%のCAGRで推移し、2028年末には2,032億米ドルの規模に成長すると予測されています。また、モノクローナル抗体の部門は、2023年の780億米ドルから、11.8%のCAGRで推移し、2028年末には1,364億米ドルの規模に成長すると予測されています。

当レポートでは、世界の個別化医療におけるナノ材料の市場を調査し、ナノ材料および技術の概要、市場影響因子および市場機会の分析、法規制環境、市場規模の推移・予測、各種区分・地域別の詳細分析、技術および特許の動向、ESGの展開、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

• ナノセラノスティクスの概要
• ポリマーナノ材料
• 磁性ナノ材料
• シリカベースナノ材料
• カーボンナノ材料
• 複合ナノ材料
• 生物ナノ材料：抗体・タンパク質・DNA
• カーボンナノチューブ
• その他のナノ材料
• 多機能ナノ材料
• ドラッグデリバリー
• 本調査の目標・目的
• 調査範囲
• 調査手法
• 情報源
• 地域区分

第2章 サマリー・ハイライト

• 市場の見通し
• 市場洞察

第3章 市場概要

• 市場概要
• セラノスティクスと個別化医療：概要
• ナノ粒子
• パッシブターゲティング
• アクティブターゲティング
• ナノテクノロジー：概要
• サイズの定義
• 形
• 表面積
• ナノセラノスティックドラッグデリバリー
• In Vivo薬物放出の研究
• 薬効
• 将来の展望

第4章 診断におけるナノデバイスとナノ材料

• 概要
• 診断における分子認識
• ナノパターン化デバイス
• 粒子
• カーボンナノチューブ
• 免疫活性化合物、タンパク質、遺伝物質のキャリアとしてのカーボンナノチューブ
• 癌光熱療法
• 他の治療用途のためのカーボンナノチューブ
• フラーレンC60
• C60の毒性
• 摂取と生体内分布
• 抗酸化特性
• 内包体
• 磁気共鳴画像
• 放射性核種
• 光線力学療法
• DNA光切断
• 癌
• 酵素、ウイルス、細菌の阻害
• 薬物と遺伝子の送達
• 磁性ナノ粒子
• 熱中症
• 磁気分離
• イメージングとデリバリー
• 脳腫瘍のデリバリー
• 前立腺癌
• 膀胱腫瘍
• 量子ドット
• アプタマー結合ナノ粒子
• ナノ粒子ベースバイオバーコード
• マルチプレックスデンドリマー
• 表面増強ラマン分光法
• 診断および医療機器産業
• 多機能ナノ粒子
• 癌治療におけるポリマーナノ粒子
• 癌イメージング用のポリマーベースのイメージングプローブ
• 癌のイメージングと治療における量子ドット
• 光線力学療法とイメージングにおける量子ドット
• 癌のイメージングと治療のための多機能イメージングナノ粒子
• 磁気共鳴イメージングと遺伝子送達のための磁性ナノ粒子
• 癌のイメージングと治療のための多機能磁性高分子ナノハイブリッド
• 光熱療法用の金ナノ粒子
• ゴールドナノシェル
• ゴールドナノロッド
• 光熱療法とイメージング用の磁性金ナノシェル
• 総論・今後の動向

第5章 医療器具関連感染に対するナノ材料に基づく治療

• 医療器具関連感染とその治療
• カテーテル関連感染症
• 軟部組織インプラント関連感染症
• バイオフィルム形成
• 医療器具関連感染を予防および治療するための一般的な方法
• 医療用途におけるナノ材料
• 個別化医療におけるナノ材料
• 抗菌ナノ材料
• 銀ナノ粒子
• 酸化亜鉛
• 鉄および酸化鉄ナノ粒子
• 酸化チタン
• カーボンナノチューブとフラーレン
• キトサン
• 細胞毒性の考慮

第6章 バイオ医療用ナノ粒子製品

• CMO
• IT
• ナノ粒子ドラッグデリバリーシステムおよび製品
• ナノ粒子ドラッグデリバリーシステム
• ナノ粒子ドラッグデリバリーに関する企業のパイプライン

第7章 治療・診断コンパニオンキット

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会

第9章 法規制環境

第10章 COVID-19の市場への影響

第11章 市場内訳：製品タイプ別

• 市場概要
• タンパク質
• モノクローナル抗体 (mAb)
• モノクローナル抗体療法
• 機構
• ナノクリスタル
• ナノクリスタルのファブリケーション
• リポソーム
• リポソームの分類・調製
• 超音波処理
• 押し出し
• 凍結融解リポソーム
• 溶剤分散法
• 洗剤除去法
• ステルスリポソーム
• 抗体-リポソーム複合体
• 医学および薬学におけるリポソームの応用
• 寄生虫疾患および感染症におけるリポソーム
• 抗癌療法におけるリポソーム
• 体外光学イメージング
• 金ナノキャリア
• 熱中症
• コントラストエンハンサー
• 放射線療法
• ナノキャリアとしての量子ドット
• 光物理特性、薬物送達および薬物放出のセンシング
• In vitroでの細胞内取り込みの可視化
• ナノキャリアの生体内分布
• 短鎖干渉RNAおよびDNAの送達

第12章 市場内訳：地域別

• 概要
• 北米
• 欧州
• アジア太平洋
• その他の地域

第13章 ESGの開発

• ESG：イントロダクション
• 環境
• 社会
• 政府
• 業界大手企業のサステナビリティ
• 製薬エンドユーザーの持続可能性
• ケーススタディ
• BCCによる総論

第14章 新興技術

• 概要
• 現在の市場動向
• 新技術
• バイオマーカー
• ディープフェノタイピング技術
• デジタル精密医療
• 遺伝学
• ヘルスIT

第15章 特許・パイプライン分析

第16章 M&Aの展望

• M&A分析
• 主要な戦略的提携

第17章 競合情勢

• 概要
• ナノバイオテクノロジーおよびナノメディシン企業の分布
• 企業シェア分析

第18章 企業プロファイル

• BRISTOL-MYERS SQUIBB
• CAMURUS AB
• CYTIMMUNE SCIENCES
• EISAI
• GILEAD SCIENCES INC.
• IPSEN PHARMA

第19章 付録：頭字語

List of Tables

• Summary Table : Global Market for Nanomaterials in Personalized Medicine, by Product Type, Through 2028

Table A : Types of Nanomaterials

Table B : Major Nanomaterial Applications in Personalized Medicine

• Table 1 : Therapies with Diagnostic Companion Kits
• Table 2 : Nanoparticle Systems Approved for Drug Delivery
• Table 3 : Imaging Modalities Used in Theranostics Nanodevices
• Table 4 : Nanoparticles Contrast Media Used for In Vivo Diagnostic Imaging
• Table 5 : Major Players in Nanoparticle Drug Development and Formulation Market
• Table 6 : Nanoparticles Used in Drug Delivery Systems
• Table 7 : List of Marketed Products Used in Different Nanotechnology-Based Techniques
• Table 8 : Major Companies in the Market for Nanoparticle Drug Development and Formulation
• Table 9 : Company Pipelines for Cardiovascular Nanoparticle Drugs
• Table 10 : Company Pipelines for CNS Disease Nanoparticle Drugs
• Table 11 : Company Pipelines for GI Disease Nanoparticle Drugs
• Table 12 : Company Pipelines for Infectious Disease Nanoparticle Drugs
• Table 13 : Company Pipelines for Cancer Nanoparticle Drugs
• Table 14 : Company Pipelines for Ophthalmic Nanoparticle Drugs
• Table 15 : Company Pipelines for Autoimmune Disease Nanoparticle Drugs
• Table 16 : Global Prevalence of Breast Cancer, by Country/Region, Through 2025
• Table 17 : Global Epidemiology of Colorectal Cancer, by Region, Through 2030
• Table 18 : Global Deaths, by Various Cancer Types, Through 2030
• Table 19 : Global Death Share, by Various Cancer Types, 2021
• Table 20 : Global Diabetes Prevalence, Estimates and Projections, 2019-2045
• Table 21 : Cases of Diabetes Worldwide, by Type, 2019
• Table 22 : Global Prevalence of Diabetes, by Type, Through 2040
• Table 23 : Global Totals of Angina Pectoris and Stroke Survivors, Through 2030
• Table 24 : Global Incidence and Prevalence of all Stroke Types, 2019
• Table 25 : Global Prevalence of Congestive Heart Failure and Stroke, Through 2030
• Table 26 : Global Market for Nanomaterials in Personalized Medicine, by Product Type, Through 2028
• Table 27 : Products of Non-monoclonal Antibody Proteins
• Table 28 : Global Market for Proteins in Personalized Medicine, by Region, Through 2028
• Table 29 : Major Companies in the Market for Monoclonal Antibodies
• Table 30 : Indications of Monoclonal Antibody Products
• Table 31 : Global Market for Monoclonal Antibodies in Personalized Medicine, by Region, Through 2028
• Table 32 : Properties of Nanocrystals
• Table 33 : Nanocrystal Drug Features
• Table 34 : Nanocrystal Fabrication Methods
• Table 35 : Nanocrystal Drugs Currently on the Market
• Table 36 : Global Market for Nanocrystals in Personalized Medicine, by Region, Through 2028
• Table 37 : Liposome Advantages
• Table 38 : Liposome-Based Drugs
• Table 39 : Major Companies in the Liposomes Market
• Table 40 : Global Market for Liposomes in Personalized Medicine, by Region, Through 2028
• Table 41 : Global Market for Gold Nanoparticles in Personalized Medicine, Through 2028
• Table 42 : Global Market for Quantum Dots in Personalized Medicine, Through 2028
• Table 43 : Global Market for Nanomaterials in Personalized Medicine, by Region, Through 2028
• Table 44 : Diabetes Estimates in North America, by Country, 2000-2045
• Table 45 : Influenza Disease Burden in U.S., by Age Group, 2019 and 2020 Influenza Season
• Table 46 : North America Market for Nanomaterials in Personalized Medicine, by Country, Through 2028
• Table 47 : Diabetes Estimates in Europe, by Country, 2000-2045
• Table 48 : European Market for Nanomaterials in Personalized Medicine, by Country, Through 2028
• Table 49 : Tuberculosis Burden of Asian Countries, by Country, 2019
• Table 50 : Diabetes Estimates for the Asia-Pacific Region, by Country, 2000-2045
• Table 51 : Asia-Pacific Market for Nanomaterials in Personalized Medicine, by Country, Through 2028
• Table 52 : Diabetes Estimates in the RoW, by Country, 2000-2045
• Table 53 : Estimation of New Cancer Cases in Africa, by Cancer Type, 2020 and 2024
• Table 54 : Rest of the World Market for Nanomaterials in Personalized Medicine, by Region, Through 2028
• Table 55 : Key Focus Areas in ESG Metrics
• Table 56 : ESG Rankings for Select Nanomaterials Personalized Medicine Companies, 2023
• Table 57 : Examples of Nanomaterials Used in Theranostics
• Table 58 : Global Patents on Nanotechnologies, by Country, 2017-2020
• Table 59 : Number of Patents, by Technology, 2001-2021*
• Table 60 : Protein Drugs
• Table 61 : Nanoparticle Systems Approved for Drug Delivery
• Table 62 : Major Strategic Alliances, 2018-2023
• Table 63 : Major Players in the Nanoparticles Drug Field
• Table 64 : Global Distribution of Nanobiotechnology and Nanomedicine Companies
• Table 65 : Bristol-Myers Squibb: Financial Performance, 2021 and 2022
• Table 66 : Bristol-Myers Squibb: Key Developments, 2019
• Table 67 : Camurus AB: Financial Performance, 2021 and 2022
• Table 68 : Camurus AB: Key Developments, 2019
• Table 69 : Cytimmune Sciences: News, 2021
• Table 70 : Eisai: Financial Performance, 2021 and 2022
• Table 71 : Eisai: News, 2021
• Table 72 : Gilead Sciences Inc.: Financial Performance, 2021 and 2022
• Table 73 : Ipsen Pharma: Financial performance, 2021 and 2022
• Table 74 : Acronyms Used in This Report

List of Figures

Figure A : Types of Nanomedicine Composed of Different Types of Materials

• Summary Figure : Global Market Shares of Nanomaterials in Personalized Medicine, by Product Type, 2022
• Figure 1 : Types of Nanomedicines Composed of Different Types of Materials
• Figure 2 : Nanoparticles Used in Personalized Medicine
• Figure 3 : Nanotechnology Used in Personalized Medicine
• Figure 4 : Shares of New Cancer Cases, Women, 2020
• Figure 5 : Shares of New Cancer Cases, Men, 2020
• Figure 6 : Global Prevalence of Breast Cancer, by Country/Region, 2015-2025
• Figure 7 : Global Epidemiology of Colorectal Cancer, by Region, 2000-2030
• Figure 8 : Global Deaths, by Various Cancer Types, 2000-2030
• Figure 9 : Global Death Share, by Various Cancer Types, 2021
• Figure 10 : Cases of Diabetes Worldwide, by Type, 2019
• Figure 11 : Global Prevalence of Diabetes, by Type, 2018 and 2040
• Figure 12 : Protein Nanoparticle Fabrication and Performance Factors
• Figure 13 : Global Market for Proteins in Personalized Medicine, 2020-2028
• Figure 14 : Global Market for Monoclonal Antibodies in Personalized Medicine, 2020-2028
• Figure 15 : Global Market for Nanocrystals in Personalized Medicine, 2020-2028
• Figure 16 : Application of Liposomes in the Drug Delivery Arena
• Figure 17 : Global Market for Liposomes in Personalized Medicine, 2020-2028
• Figure 18 : Global Market for Gold Nanoparticles in Personalized Medicine, 2020-2028
• Figure 19 : Global Market for Quantum Dots in Personalized Medicine, 2020-2028
• Figure 20 : Global Market Shares of Nanomaterials in Personalized Medicine, by Region, 2022
• Figure 21 : North America Market for Nanomaterials in Personalized Medicine, by Country, 2020-2028
• Figure 22 : Cancer Diagnosis Share in Europe, by Gender, 2020
• Figure 23 : European Market for Nanomaterials in Personalized Medicine, by Country, 2020-2028
• Figure 24 : Asia-Pacific Market for Nanomaterials in Personalized Medicine, by Country, 2020-2028
• Figure 25 : Rest of the World Market for Nanomaterials in Personalized Medicine, by Region, 2020-2028
• Figure 26 : How a Strong ESG Proposition Benefits Businesses
• Figure 27 : ESG-Adoption Level Across All the Industries, 2021 and 2022
• Figure 28 : The Ten Business Sustainability Trends Identified for 2022
• Figure 29 : Key Sustainable Practices Being Implemented in Research Laboratories
• Figure 30 : Emerging Technologies in the Nanomaterials in Personalized Medicine Market
• Figure 31 : Global Market Shares of Nanoparticles in Personalized Medicine, by Company, 2022
• Figure 32 : Bristol-Myers Squibb: Financial Performance, 2021 and 2022
• Figure 33 : Bristol-Myers Squibb: Revenue Share, by Country/Region, 2022
• Figure 34 : Camurus AB: Financial Performance, 2021 and 2022
• Figure 35 : Camurus AB: Revenue Share, by Country/Region, 2022
• Figure 36 : Eisai: Financial Performance, 2021 and 2022
• Figure 37 : Eisai: Revenue Share, by Country/Region, 2022
• Figure 38 : Gilead Sciences Inc.: Financial Performance, 2021 and 2022
• Figure 39 : Gilead Sciences Inc.: Revenue Share, by Country/Region, 2022
• Figure 40 : Ipsen Pharma: Financial Performance, 2021 and 2022
• Figure 41 : Ipsen Pharma: Revenue Share, by Segment, 2022
• Figure 42 : Ipsen Pharma: Revenue Share, by Country/Region, 2022

Highlights:

The global market for nanomaterials in personalized medicine is expected to increase from $346.7 billion in 2023 to $592.0 billion by the end of 2028, with a compound annual growth rate (CAGR) of 11.3% during the forecast period of 2023-2028.

Proteins market for nanomaterials in personalized medicine is expected to increase from $112.8 billion in 2023 to $203.2 billion by the end of 2028, with a CAGR of 12.5% during the forecast period of 2023-2028.

Monoclonal antibodies market for nanomaterials in personalized medicine is expected to increase from $78.0 billion in 2023 to $136.4 billion by the end of 2028, with a CAGR of 11.8% during the forecast period of 2023-2028.

Report Scope:

The current report will provide detailed exposure to nanomaterials in the personalized medicine market. This report analyzes the market trends of nanomaterials in personalized medicine with data from 2022, estimates from 2023, and projections of compound annual growth rates through 2028 (forecast period of 2023 to 2028. This report will highlight the current and future market potential of nanomaterials in personalized medicine, with a detailed analysis of the competitive environment. The report will cover regulatory scenarios, drivers, restraints, and opportunities. The report also covers market projections for 2028 and the market share for key market players.

The scope of the market in this report is segmented into product type and region. The product type of nanomaterials in personalized medicine is further segmented into proteins, monoclonal antibodies, nanocrystals, liposomes, gold nanoparticles, and quantum dots. The regional market analysis of nanomaterials in personalized medicine is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Detailed analysis of major countries such as the U.S., Germany, the U.K., Italy, France, Japan, China, and India is covered within the regional segments. For market estimates, data is provided for 2022 as the base year, with an estimate for 2023 and forecast value for 2028.

Report Includes:

• 27 data tables and 50 additional tables
• An overview of the global market for nanomaterials in personalized medicine
• Estimates of the market size and analyses of global market trends with data from 2020-2023, and projections of compound annual growth rates (CAGRs) through 2028
• Discussions of the current and future market potential, and quantification of the market by product type and region
• Description of emerging technologies such as biomarkers, deep phenotyping, digital precision medicine, genetics, and health information technology; and discussion on ESG trends and pharma end user sustainability in the industry
• Details about various terms such as monoclonal antibodies (mAbs), nanocrystals, liposomes, their usage in vaccine production, and discussion on how quantum dots work as nanocarriers
• Insights into advances in nanotechnology by using next-generation vaccines regimes and an overview of the government investments in healthcare sectors
• Coverage of projects funded by the National Human Genome Research Institute (NHGRI) and other private and government investments, and information on Sanofi in-licensed Exscientia's innovative bispecific small molecule candidate
• Assessments of innovations and technological advances, the adoption of precision healthcare, and regulatory scenarios, and market drivers, restraints, and opportunities
• Analysis of the market shares of the key companies and their proprietary technologies, patents, partnerships and alliances and other key strategies
• Company profiles of major players within the industry, including Bristol-Myers Squibb, Eisai, Gilead Sciences Inc., and Ipsen Pharma

Table of Contents

Chapter 1 Introduction

• Overview of Nanotheranostics
• Polymeric Nanomaterials
• Magnetic Nanomaterials
• Silica-Based Nanomaterials
• Carbon Nanomaterials
• Composite Nanomaterials
• Biologic Nanomaterials: Antibody, Proteins and DNA
• Carbon Nanotubes
• Other Nanomaterials
• Multifunctional Nanomaterials
• Drug Delivery
• Study Goals and Objectives
• Reasons for Doing This Study
• Scope of Report
• What's New in this Update?
• Methodology
• Information Sources
• Geographic Breakdown

Chapter 2 Summary and Highlights

• Market Outlook
• Market Insights

Chapter 3 Market Overview

• Market Overview
• Theranostics and Personalized Medicines Overview
• Nanoparticles
• Passive Targeting
• Active Targeting
• Nanotechnology Overview
• Size Definition
• Shape
• Surface Area
• Nanotheranostic Drug Delivery
• In Vivo Drug-Release Studies
• Drug Efficacy
• Future Perspectives

Chapter 4 Nanodevices and Nanomaterials in Diagnostics

• Overview
• Molecular Recognition in Diagnosis
• Nanopatterned Devices
• Particles
• Carbon Nanotubes
• Carbon Nanotubes as a Carriers of Immunoactive Compounds, Proteins and Genetic Materials
• Cancer Photothermal Therapy
• Carbon Nanotubes for Other Therapeutic Applications
• Fullerene C60
• C60 Toxicity
• Uptake and Biodistribution
• Antioxidant Properties
• Endohedrals
• Magnetic Resonance Imaging
• Radionuclides
• Photodynamic Therapy
• DNA Photocleavage
• Cancer
• Enzymes, Viruses, and Bacteria Inhibition
• Drug and Gene Delivery
• Magnetic Nanoparticles
• Hyperthermia
• Magnetic Separation
• Imaging and Delivery
• Brain Tumor Delivery
• Prostate Cancer
• Bladder Tumors
• Quantum Dots
• Aptamer-Conjugated Nanoparticles
• Nanoparticle-Based Bio-Bar Codes
• Multiplex Dendrimers
• Surface Enhanced Raman Spectroscopy
• Diagnostic and Medical Device Industry
• Multifunctional Nanoparticles
• Polymeric Nanoparticles in Cancer Therapy
• Polymeric-Based Imaging Probes for Cancer Imaging
• Quantum Dots in Cancer Imaging and Therapy
• Quantum Dots in Photodynamic Therapy and Imaging
• Multifunctional Imaging Nanoparticles for Cancer Imaging and Therapy
• Magnetic Nanoparticles for Magnetic Resonance Imaging and Gene Delivery
• Multifunctional Magneto-Polymeric Nanohybrids for Cancer Imaging and Therapy
• Gold Nanoparticles for Photothermal Therapy
• Gold Nanoshells
• Gold Nanorods
• Magnetic Gold Nanoshells for Photothermal Therapy and Imaging
• Conclusion and Future Trends

Chapter 5 Treatments Based on Nanomaterial for Infections Associated with Medical Devices

• Infections Associated with Medical Devices and Their Treatments
• Catheter-Associated Infections
• Soft-Tissue-Implant-Associated Infections
• Biofilm Formation
• Common Methods for Preventing and Treating Medical Device-Associated Infections
• Nanomaterials in Medical Applications
• Nanomaterials in Personalized Medicine
• Antimicrobial Nanomaterials
• Silver Nanoparticles
• Zinc Oxide
• Iron and Iron-Oxide Nanoparticles
• Titanium Oxide
• Carbon Nanotubes and Fullerenes
• Chitosan
• Cytotoxicity Consideration

Chapter 6 Biomedical Nanoparticle Products

• Introduction
• Contract Manufacturing Organizations
• Information Technology
• Nanoparticle Drug Delivery Systems and Products
• Nanoparticle Drug Delivery Systems
• Company Pipelines for Nanoparticle Drug Delivery

Chapter 7 Therapeutic and Diagnostic Companion Kits

• Introduction

Chapter 8 Market Dynamics

• Market Drivers
• Rising Prevalence of Chronic Diseases Globally
• Rising Cancer Cases Globally
• Cancer Mortality
• Increasing Number of Diabetes Cases Worldwide
• Rising Worldwide Cases of Hypercholesterolemia
• Other major drivers in the personalized medicine market are:
• Market Restraints
• Challenges with Personalized Medicine
• Market Opportunities
• Nanodrug Delivery for the Treatment of Neurological Disorders
• Increasing Government Investment in Healthcare Sectors
• Rising Healthcare Costs
• Consumer Expectations

Chapter 9 Regulatory Landscape

• Overview
• Physicochemical Properties of Nanoproducts Differ Compared to Their Larger Counterparts
• Regulatory Issues in Nanotechnology
• Nanomedicines in the Pharmaceutical Market
• Market Access and Pharmacoeconomics

Chapter 10 Impact of COVID-19 on the Market

• Overview
• Structure of COVID-19 and Penetration
• COVID-19 Crisis
• Impact of COVID-19 on Nanomaterials in Personalized Medicine
• Novel Coronavirus Relying on Various Approaches
• Challenges in Vaccine Disruptions
• Components and Methods in the Design of a Vaccine
• Antigens
• Adjuvants
• Nanoparticles/Nanocarriers
• Devices
• Next-Generation Vaccines Enabled Through Advances in Nanotechnology
• Conclusions Regarding Use of Nanotechnology to Combat COVID-19
• COVID-19 Measures

Chapter 11 Market Breakdown by Product Type

• Market Overview
• Proteins
• Monoclonal Antibodies (mAbs)
• Monoclonal Antibody Therapy
• Mechanism
• Nanocrystals
• Nanocrystals Fabrication
• Liposomes
• Liposome Classification and Preparation
• Sonication
• Extrusion
• Freeze-Thawed Liposomes
• Solvent Dispersion Method
• Detergent-Removal Method
• Stealth Liposome
• Antibody-Liposome Conjugate
• Liposome Application in Medicine and Pharmacology
• Liposomes in Parasite Diseases and Infections
• Liposomes in Anticancer Therapies
• In Vitro Optical Imaging
• Gold Nanocarrier
• Hyperthermia
• Contrast Enhancers
• Radiotherapy
• Quantum Dots as Nanocarriers
• Photophysical Properties, Drug-Delivery and Drug-Release Sensing
• Visualizing Intracellular Uptake In Vitro
• Nanocarrier Biodistribution In Vivo
• Short Interfering RNA and DNA delivery

Chapter 12 Market Breakdown by Region

• Overview
• North America
• U.S. Market Size and Forecast
• Canada Market Size and Forecast
• Europe
• Germany Market Size and Forecast
• U.K. Market Size and Forecast
• France Market Size and Forecast
• Italy Market Size and Forecast
• Spain Market Size and Forecast
• Rest of European Market Size and Forecast
• Asia-Pacific
• China Market Size and Forecast
• Japan Market Size and Forecast
• India Market Size and Forecast
• South Korea Market Size and Forecast
• Rest of Asia-Pacific Market Size and Forecast
• Rest of the World
• South America Market Size and Forecast
• Middle East and Africa Market Size and Forecast

Chapter 13 ESG Development

• Introduction to ESG
• Environmental
• Social
• Government
• The Sustainability of Major Companies in the Industry
• Pharma End User Sustainability in the Industry
• Case Study
• Concluding Remarks from BCC

Chapter 14 Emerging Technologies

• Overview
• Current Market Trends
• Emerging Technologies
• Biomarkers
• Deep Phenotyping Technologies
• Digital Precision Medicine
• Genetics
• Health Information Technology

Chapter 15 Patents and Pipeline Analysis

• Overview
• Patent Analysis
• Pipeline Analysis

Chapter 16 M&A Outlook

• M&A Analysis
• Major Strategic Alliances

Chapter 17 Competitive Landscape

• Overview
• Distribution of Nanobiotechnology and Nanomedicine Companies
• Company Share Analysis

Chapter 18 Company Profiles

• BRISTOL-MYERS SQUIBB
• CAMURUS AB
• CYTIMMUNE SCIENCES
• EISAI
• GILEAD SCIENCES INC.
• IPSEN PHARMA

Chapter 19 Appendix: Acronyms